Q-omics provides the consensus-scored CXADRP1 profile across patient tissues and cancer cell-line models. CXADRP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CXADRP1 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, CXADRP1 RNA expression shows 5,503 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, BRCA, and STAD as cancer lineages where CXADRP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXADRP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXADRP1 survival associations across molecular data types. CXADRP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXADRP1 RNA expression–survival associations across cancer types. High CXADRP1 expression shows unfavorable associations in COAD, OV, KIRP, ESCA, HNSC and THCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify COAD as the clearest survival context for CXADRP1 RNA expression.
This table summarizes CXADRP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CXADRP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXADRP1 shows higher tumor expression in BRCA, ESCA and LUSC. The BRCA box plot shows higher CXADRP1 RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p = .009).
This table shows molecular features associated with CXADRP1 in patient tissues and cancer cell lines. In patient samples, CXADRP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
